Month: August 2023

Total revenue for the first half of 2023 was approximately $1.65 million, an increase of approximately 15% compared to approximately $1.44 million in the first half of 2022 Signed FIND R&D collaboration contract extension Entered distribution agreement with Fisher Healthcare for the distribution of the Unyvero A50 platform in the U.S. Management conference call is scheduled for August 10, 2023, at 4:30 p.m. ETROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update. Second...

Management forecasts to reach gross margin positive in Q3 2023Term sheet executed with lead investor for up to $150 million secured debt facility Q2 2023 Financial HighlightsRevenue Growth: Q2’23 revenue of $28 million grew 72% year-over-year compared to $16 million in Q2’22. Gross Margin Improvement: Higher quality revenue, lower fixed costs, improved factory efficiencies, favorable mix, and product cost reductions all drove improving margins y/y:Gross loss improved from ($23 million) in Q2’22 to ($14 million) in Q2’23.Reduction in Operating Expenses: 2022 and 2023 cost reductions resulted in:R&D expense declined by 54% y/y from Q2’22 to Q2’23. SG&A expense declined by 42% y/y from Q2’22 to Q2’23.Continued Progress to Profitability: Revenue growth, improving gross margins, and lower operating expense resulted in:Loss...

Q3’23 Revenue Increased 22% to $14.7M with 2nd Consecutive Quarter of Positive Operating Income of $0.1M Gross Margin up 200 Basis Points to 44% in Q3’23 Management to Host Conference Call Today at 5:00 p.m. ET Brooklyn, NY, Aug. 10, 2023 (GLOBE NEWSWIRE) —  – Cemtrex Inc. (NASDAQ: CETX, CETXP), an advanced security technology and industrial services company, has reported its financial and operational results for the third quarter ended June 30, 2023. Key Third Quarter FY 2023 and Subsequent HighlightsRevenue for Q3’23 increased 22% to $14.7 million, compared to revenue of $12.1 million for Q3’22.Security segment revenues increased 36% to $9.0 million in Q3’23 as border protection vertical drives new order volumes for Vicon.Gross margin up 200 basis points to 44% in Q3’23 from 42% in the prior year quarter Operating...

Revenue up 370% from Q2 2022 Gross profit up 691% from Q2 2022 Operating Expenses up 122% from Q2 2022 Positive adjusted EBITDAMINNETONKA, Minn., Aug. 10, 2023 (GLOBE NEWSWIRE) — Pineapple Energy Inc. (NASDAQ: PEGY), a leading provider of sustainable solar energy and back-up power to households and small businesses, today announced financial results for the second quarter ended June 30, 2023. Pineapple CEO Kyle Udseth commented, “We were able to deliver an excellent second quarter, against a backdrop of uncertainty in the residential solar industry and counter to the weak results turned in by many of our larger public peers. This was not by accident. We kept the focus on execution and in our Hawaii and New York markets, while responsibly managing corporate overhead. Our strategy is proving out, as selective acquisitions of leading...

BRISBANE, Calif., Aug. 10, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-classi therapeutics that combine both targeted and immune-mediated mechanisms, today reported financial results for the quarter ended June 30, 2023 and provided a corporate update. “2023 continues to be a productive and potentially transformative year for Tempest,” said Stephen Brady, chief executive officer of Tempest. “In the second quarter, we presented data from our second clinical program, TPST-1495, the company’s novel dual EP2/EP4 antagonist designed to selectively modulate the prostaglandin pathway, both at ASCO and in a paper published in Cancer Research Communications. These presentations were made on the heels of announcing early exciting triplet data from our lead TPST-1120...

Conference call and webcast on August 10, 2023 at 5 p.m. ET RADNOR, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) — Safeguard Scientifics, Inc. (NASDAQ:SFE) (“Safeguard” or the “Company”) today announced financial results for the three and six months ended June 30, 2023. SECOND QUARTER 2023 HIGHLIGHTSFinancial ResultsCash, cash equivalents and restricted cash totaled $15.1 million at June 30, 2023. The carrying value of the Company’s ownership interests totaled $13.0 million at June 30, 2023. The total cost of the Company’s ownership interests was $138.4 million. Net loss for the three months ended June 30, 2023 was $2.9 million, or $0.18 per share, as compared with a net income of $0.5 million, or $0.03 per share, for the same period in 2022. Net loss for the six months ended June 30, 2023 was $6.3 million, or $0.39 per share, as compared...

Record Fundraising and Deployment Drives Double-Digit Revenue Growth DALLAS, Aug. 10, 2023 (GLOBE NEWSWIRE) — P10, Inc. (NYSE: PX), a leading private markets solutions provider, today reported financial results for the second quarter ended June 30, 2023. Second Quarter 2023 Financial Highlights:Fee Paying Assets Under Management: $22.2 billion, a 20% increase year over year. Revenue: $62.5 million, a 34% increase year over year. GAAP Net Income: $2.1 million, an 81% decrease year over year. Adjusted EBITDA: $34.8 million, a 35% increase year over year. Adjusted Net Income: $26.7 million, a 15% increase year over year. Fully diluted GAAP EPS: $.02, a 78% decrease year over year. Fully diluted ANI per share: $.22, a 16% increase year over year.A presentation of the quarterly financials may be accessed here and is available on...

WINSTON-SALEM, N.C., Aug. 10, 2023 (GLOBE NEWSWIRE) — ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on dialysis-free living for those with chronic kidney disease (CKD), today announced financial results for the second quarter ended June 30, 2023, and provided an update on recent corporate developments. “In the second quarter, and throughout the first half of 2023, we steadily advanced our REACT development programs, including our initial Phase 3 study, proact 1, that is assessing the potential for REACT to delay or halt the progression of moderate to severe diabetic CKD,” said Dr. Tim Bertram, Chief Executive Officer of ProKidney. “Looking ahead, we expect to reach several important inflection points in the coming months, including updated interim...

Gross profit margin increased to 50.2%, an improvement of 140 basis points sequentially Reaffirms Net Revenue guidance for the full year of 2023 of at least $305 million and Adjusted EBITDA from continuing operations1 of at least $58 million TORONTO, Aug. 10, 2023 (GLOBE NEWSWIRE) — TerrAscend Corp. (“TerrAscend” or the “Company”) (TSX: TSND) (OTCQX: TSNDF), a leading North American cannabis operator, today reported its financial results for the second quarter ended June 30, 2023. All amounts are expressed in U.S. dollars and are prepared under U.S. Generally Accepted Accounting Principles (GAAP), unless indicated otherwise. The following financial measures are reported as results from continuing operations due to the shutdown of the licensed producer business in Canada, which is reported as discontinued operations for all of 2022....

MINNEAPOLIS , Aug. 10, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2023. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2023 and Recent Highlights PartnershipsDivestiture of assets within eflornithine (DFMO) pediatric neuroblastoma program to US WorldMeds® for an upfront payment of $400,000 and contingent payments totaling up to an additional $9.1 million. Regained the North American rights to develop and commercialize Flynpovi tm (the combination of CPP-1X (eflornithine) and sulindac) in patients with familial adenomatous polyposis (FAP).ClinicalOpened...